November 04, 2021
1 min read
Source/Disclosures
Published by:
Neumiller JJ. et al. Optimal delivery of diabetes and CKD therapies by multidisciplinary care models. Presented at: ASN Kidney Week; Nov. 4-7, 2021 (virtual meeting).
Disclosures:
Neumiller reports being an employee of Washington State University College of Pharmacy and Pharmaceutical Sciences; consulting for Novo Nordisk; receiving honoraria from the American Diabetes Association as a member of their editorial board; and serving on the speakers bureau for Dexcom.
Health care providers need to consider multidisciplinary care models to improve outcomes for patients with diabetic kidney disease, according to speaker at ASN Kidney Week.
“The current evidence and guidelines for the treatment of diabetes and CKD are rapidly evolving, and I think most would agree that utilization of multidisciplinary models of care is critical to ensure that patients with diabetes and CKD receive new and established therapies to optimize health outcomes,” Joshua J. Neumiller, PharmD, vice-chair and Allen I. White Distinguished Professor in the department of pharmacotherapy at Washington State University, said.
A variety of guidelines from the American Diabetes Association, Kidney Disease: Improving Global Outcomes (KDIGO) and other groups outline recommendations for drug therapy for the diabetic kidney disease patient, Neumiller said.
“Recent guidelines include taking into consideration the patient’s cardiovascular history when selecting a diabetes medication to further mitigate cardiovascular risk,” he said.
KDIGO guidelines provide guidance on the use of antihyperglycemic use in patients with type 2 diabetes and chronic kidney disease, along with “intensification of lifestyle intervention,” Neumiller said, along with first-line pharmacy management using metformin or SGLT-2 inhibitors.
Key to successful drug therapy is a comprehensive diabetes and chronic kidney disease management approach, he said.
“KDIGO supports management of all patients with a comprehensive approach that includes blood pressure and lipid control, facilitates smoking cessation where applicable, and provides education and support for appropriate level of education and physical activity,” he said.
Barriers to improvement in diabetic CKD patient care remain, which include suboptimal identification of CKD, lack of disease awareness and poor patient education, Neumiller said. “Likewise, we need to do a better job of diabetes and CKD self-management education and support, we need to increase use of SGLT-2 inhibitors in patients with low eGFR and improve affordability of these drugs for our patients,” he said.
American Society of Nephrology Annual Meeting
